According to the American Psychiatric Association, “Opioid use disorder is a chronic lifelong disorder, with serious potential consequences including disability, relapses, and death.”
Opioid Use Disorder (OUD) is currently the number one cause of death in Americans under 50 and the COVID-19 pandemic is expected to make the crisis worse.
According to experts, health visits with their provider is crucial for individuals with OUD. Unfortunately, the pandemic has placed restrictions on in-person visits these individuals desperately need.
“Prior to COVID-19, we were not able to initiate outpatient buprenorphine treatment by telehealth as an outpatient practice, but the laws have changed during the pandemic,” said Michelle Lofwall, M.D., professor of behavioral science and psychiatry in the University of Kentucky College of Medicine.
“We are still offering in-person visits as well, under strict COVID protocols. There are some patients who still benefit from and need in-person visits – whether it is because they need the in-person human interaction or there is a need for a physical exam that cannot be done via telemedicine, or they may not have access to the technology or Wi-Fi that allows for videoconferencing.”
Nationwide Drug Testing Service knows the importance of kindness and understanding in the midst of difficult times. That’s why at Nationwide Drug Testing Service, our staff is not only understanding and considerate, but knowledgeable as well. From the moment you contact us, you work with a professional, well-trained Representative who stays with you throughout the entire process.
Nationwide Drug Testing Services is one of the largest accredited drug testing networks in the U.S. We offer testing in every state Nationwide, for affordable, Same-Day-Appointment Drug Testing and Fast, Accurate results.